Surgery plus maintenance medicines for advanced ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and your cancer is confirmed as epithelial ovarian cancer (or fallopian tube or primary peritoneal cancer).
- Your cancer is stage IIIC or IV, and scans show a “low to high” tumor burden but a specific cPCI score of 12 or less.
- Doctors believe they can remove all visible tumor during surgery (complete cytoreduction) based on scan results.
- You agree to genetic/genome testing for BRCA and HRD before starting treatment.
- Your general condition is good enough for treatment (ECOG 0–2), and your blood, kidney, and liver labs are within required limits.
- You must be able to start and complete chemotherapy and the planned follow-up visits, and you must sign informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks if adjusting the timing of surgery (interval debulking surgery) after chemotherapy can improve outcomes for people with advanced ovarian cancer. It's for those who cannot have surgery right away and will receive chemotherapy first.
This trial compares two ways of treating advanced ovarian cancer: having surgery first, or having chemotherapy first followed by surgery. The goal is to see which approach improves outcomes for patients.
This Phase 2 trial tests giving chemotherapy before surgery, then continuing two medicines afterward (olaparib and pembrolizumab). It’s designed for people with newly diagnosed Stage III/IV ovarian, fallopian tube, or primary peritoneal cancer who may benefit from tighter control of the disease.
This trial is testing a combination of two new immunotherapy drugs (iparomlimab and tuvonralimab) given before surgery and together with chemotherapy for advanced ovarian cancer. It aims to see if this approach can shrink the cancer more effectively and improve outcomes.
This trial tests whether adding immunotherapy (a treatment that boosts your immune system) to surgery helps people whose ovarian cancer has returned and is sensitive to chemotherapy. It aims to see if this combination can improve outcomes for patients with certain biomarkers.
This trial tests whether doing additional (“secondary”) tumor-removal surgery can help people with ovarian, fallopian tube, or primary peritoneal cancer that has returned after PARP inhibitor maintenance. It focuses on people whose cancer can likely be fully removed and who are considered good candidates for surgery and follow-up treatment.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.